Norway Savings Bank increased its holdings in Becton Dickinson and Co (NYSE:BDX) by 51.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,097 shares of the medical instruments supplier’s stock after buying an additional 1,052 shares during the period. Norway Savings Bank’s holdings in Becton Dickinson and were worth $663,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also modified their holdings of the company. Cottage Street Advisors LLC acquired a new position in shares of Becton Dickinson and during the fourth quarter worth $214,000. Gofen & Glossberg LLC IL increased its position in shares of Becton Dickinson and by 4.8% during the fourth quarter. Gofen & Glossberg LLC IL now owns 34,325 shares of the medical instruments supplier’s stock worth $7,348,000 after purchasing an additional 1,571 shares in the last quarter. Pennsylvania Trust Co increased its position in shares of Becton Dickinson and by 9.4% during the fourth quarter. Pennsylvania Trust Co now owns 25,090 shares of the medical instruments supplier’s stock worth $5,553,000 after purchasing an additional 2,153 shares in the last quarter. Atria Investments LLC increased its position in shares of Becton Dickinson and by 41.9% during the fourth quarter. Atria Investments LLC now owns 1,476 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 436 shares in the last quarter. Finally, KCS Wealth Advisory acquired a new position in shares of Becton Dickinson and during the fourth quarter worth $357,000. 75.54% of the stock is owned by institutional investors.
Becton Dickinson and Co (NYSE BDX) traded up $1.89 during midday trading on Tuesday, hitting $227.71. The company had a trading volume of 1,870,400 shares, compared to its average volume of 1,668,844. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. Becton Dickinson and Co has a 52-week low of $169.19 and a 52-week high of $229.68. The firm has a market cap of $52,630.00, a P/E ratio of 48.97, a price-to-earnings-growth ratio of 1.78 and a beta of 1.07.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same period in the prior year, the company earned $2.12 earnings per share. The firm’s revenue was down 2.0% on a year-over-year basis. sell-side analysts predict that Becton Dickinson and Co will post 10.66 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 8th were issued a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.32%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date was Thursday, December 7th. Becton Dickinson and’s dividend payout ratio is presently 64.52%.
BDX has been the topic of a number of recent analyst reports. Morgan Stanley upped their price target on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank of Canada reissued a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Wells Fargo & Co assumed coverage on Becton Dickinson and in a research report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $230.20.
COPYRIGHT VIOLATION WARNING: “Norway Savings Bank Acquires 1,052 Shares of Becton Dickinson and Co (BDX)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/16/norway-savings-bank-acquires-1052-shares-of-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.